Life sciences, health care, and chemical companies are the major end users of lab equipment. Cash flows of major companies within these sectors are increasingly subjected to higher scrutiny due to a rise in M&A activities and their increased investments in emerging markets.
Did somebody order more dNTPs? Where is the p53 antibody? Every day, simple questions like these disrupt workflow and distract researchers from their experiments